Desogestrel

Desogestrel

Clinical data
ATC code	G03AC09 (WHO)
Pharmacokinetic data
Protein binding	98.3%
Identifiers
IUPAC name 13-ethyl-17-ethynyl- 11-methylidene- 1,2,3,6,7,8,9,10,12,13,14,15, 16,17- tetradecahydrocyclopenta[a] phenanthren-17-ol
CAS Number	54024-22-5
PubChem CID	40973
DrugBank	APRD00762
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H30O
Molar mass	310.473 g/mol

WikiDoc Resources for Desogestrel
Articles
Most recent articles on Desogestrel Most cited articles on Desogestrel Review articles on Desogestrel Articles on Desogestrel in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Desogestrel Images of Desogestrel Photos of Desogestrel Podcasts & MP3s on Desogestrel Videos on Desogestrel
Evidence Based Medicine
Cochrane Collaboration on Desogestrel Bandolier on Desogestrel TRIP on Desogestrel
Clinical Trials
Ongoing Trials on Desogestrel at Clinical Trials.gov Trial results on Desogestrel Clinical Trials on Desogestrel at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Desogestrel NICE Guidance on Desogestrel NHS PRODIGY Guidance FDA on Desogestrel CDC on Desogestrel
Books
Books on Desogestrel
News
Desogestrel in the news Be alerted to news on Desogestrel News trends on Desogestrel
Commentary
Blogs on Desogestrel
Definitions
Definitions of Desogestrel
Patient Resources / Community
Patient resources on Desogestrel Discussion groups on Desogestrel Patient Handouts on Desogestrel Directions to Hospitals Treating Desogestrel Risk calculators and risk factors for Desogestrel
Healthcare Provider Resources
Symptoms of Desogestrel Causes & Risk Factors for Desogestrel Diagnostic studies for Desogestrel Treatment of Desogestrel
Continuing Medical Education (CME)
CME Programs on Desogestrel
International
Desogestrel en Espanol Desogestrel en Francais
Business
Desogestrel in the Marketplace Patents on Desogestrel
Experimental / Informatics
List of terms related to Desogestrel

Desogestrel is a molecule used in hormonal contraceptives.

Controversy

In February of 2007, the consumer adovcacy group Public Citizen released a petition requesting that the FDA ban oral contraceptives containing desogestrel, citing studies going as far back as 1995 that suggest the risk of dangerous blood clots is doubled for women on such pills in comparison to other oral contraceptives.

Most combined oral contraceptive pills (COCPs, or simply OCs) on the market today contain both an estrogen compound (ethinyl estradiol is common) plus a progestin (a progesterone-like compound) such as desogestrel.

As such, desogestrel-containing birth control pills are sometimes referred to as "third generation" oral contraceptives. Drugs cited specifically in the petition include Apri-28, Cyclessa, Desogen, Kariva, Mircette, Ortho-Cept, Reclipsen, Velivet and some generic pills. Birth control pills that are considered "second generation" (Ortho Tri-Cyclen, for example) contain an estrogen and a progestin, but the progestin is different, such as levonorgestrel.

The dispute is whether third generation OCs are less safe than the second generations OCs, which are considered the current "gold standard" in terms of oral contraceptive safety.

See also

• Progestin

References

• Public Citizen’s Health Research Group: Petition to the U.S. Food and Drug Administration to Ban Third Generation Oral Contraceptives Containing Desogestrel due to Increased Risk of Venous Thrombosis HRG Publication #1799, 2007